Bionano Genomics Inc (BNGO)
$0.24 $0.00 (2.12%) 4:38 PM 12/13/24
NASDAQ | $USD | Medical Instruments & SuppliesStock Data
-
Market Cap
$23.84M -
Day's Range
$0.23 - $0.24 -
Volume
2,891,300 -
52 Week Low / High
$0.20 - $2.27 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 0
- Strong Buy
- 0
- Buy
- 4
- Hold
- 0
- Sell
- 0
- Strong Sell
- $13.20
- Target Price
Company News
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research — Jun 20th, 2024
Bionano Genomics Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflow...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
-
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ... — Oct 9th, 2024
Revenue: $7.8 million for Q2 2024, a 10% year-over-year decrease. OGM Installed Base: Grew to 363 systems, a net increase of 16 systems and 29% growth year-over-year. Flow Cells Sold: 6,165 in Q2 2024, a 13% year-over-year decrease. GAAP Gross Margin: 33% in Q2 2024, up from 27% in Q2 2023...
Portfolio
Comprised of 1 portfolios